Avigen Inc. is shifting focus to its product for neuropathic pain and opioid addiction, after a study of its drug for muscle spasms in patients with multiple sclerosis missed the mark, sending the company's shares tumbling 81.2 percent Tuesday. (BioWorld Today) Read More
